Page last updated: 2024-11-05

2-ethylphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Ethylphenol, also known as o-ethylphenol, is a colorless to pale yellow liquid with a phenolic odor. It is a synthetic compound that can be synthesized through various methods, including the alkylation of phenol with ethyl chloride in the presence of a catalyst. 2-Ethylphenol is used as an intermediate in the production of pharmaceuticals, antioxidants, and dyes. It is also found naturally in foods, such as coffee, tea, and wine. Research on 2-Ethylphenol focuses on its potential health effects, particularly its antioxidant properties and neuroprotective effects. Studies have shown that 2-Ethylphenol may have anti-inflammatory and anti-cancer properties. It is also being investigated for its potential use in the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. However, it is important to note that further research is needed to fully understand the safety and efficacy of 2-Ethylphenol.'

2-ethylphenol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6997
CHEMBL ID321029
CHEBI ID34275
SCHEMBL ID51108
MeSH IDM0480133

Synonyms (66)

Synonym
BIDD:ER0661
25429-37-2
phenol, ethyl-
SGCUT00114
nsc10112
phlorol
phenol, o-ethyl-
phenol, 2-ethyl-
90-00-6
o-ethylphenol
1-ethyl-2-hydroxybenzene
2-ethylphenol
1-hydroxy-2-ethylbenzene
nsc-10112
NCGC00091780-01
o-ethyl phenol
inchi=1/c8h10o/c1-2-7-5-3-4-6-8(7)9/h3-6,9h,2h2,1h
einecs 201-958-4
nsc 10112
ccris 6038
florol [czech]
benzene, 1-ethyl-2-hydroxy-
hsdb 5267
brn 1099397
TO_000008
2-ethylphenol, 99%
jz1 ,
CHEMBL321029
chebi:34275 ,
2-ethyl-phenol
E0160
ethylphenol
AKOS000119353
NCGC00091780-02
NCGC00256439-01
dtxsid1022479 ,
dtxcid702479
cas-90-00-6
tox21_302885
NCGC00259876-01
tox21_202327
c27y543kva ,
unii-c27y543kva
florol
4-06-00-03011 (beilstein handbook reference)
355o0p4ju7 ,
unii-355o0p4ju7
FT-0612290
metacresol impurity e [ep impurity]
o-hydroxyethylbenzene
2-ethylphenol [mi]
SCHEMBL51108
2-ethyl phenol
STR06133
mfcd00002249
J-509333
2-ethylphenol, pestanal(r), analytical standard
2-ethylphenol 100 microg/ml in methanol
721429-63-6
2-ethylphenol-d10
Q27115959
2-ethylphenol 1000 microg/ml in methanol
SY012952
CS-0152504
EN300-20199
Z104477226
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency39.71960.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.67223.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.48210.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency68.24100.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.20580.001022.650876.6163AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.44020.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.46720.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.81990.001530.607315,848.9004AID1224848; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency54.72080.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.42320.000229.305416,493.5996AID1259244; AID743069; AID743075
thyroid stimulating hormone receptorHomo sapiens (human)Potency48.31090.001628.015177.1139AID1224843
activating transcription factor 6Homo sapiens (human)Potency0.02440.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.28890.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency50.23110.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.57800.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency19.23290.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency19.23290.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.21 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index52.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]